Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.7794
+0.0289 (3.85%)
At close: Oct 30, 2025, 4:00 PM EDT
0.7564
-0.0230 (-2.95%)
Pre-market: Oct 31, 2025, 4:11 AM EDT
Adicet Bio Employees
Adicet Bio had 152 employees as of December 31, 2024. The number of employees increased by 9 or 6.29% compared to the previous year.
Employees
152
Change (1Y)
9
Growth (1Y)
6.29%
Revenue / Employee
n/a
Profits / Employee
-$780,500
Market Cap
126.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 152 | 9 | 6.29% |
| Dec 31, 2023 | 143 | 11 | 8.33% |
| Dec 31, 2022 | 132 | 46 | 53.49% |
| Dec 31, 2021 | 86 | 4 | 4.88% |
| Dec 31, 2020 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACET News
- 2 days ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire
- 14 days ago - Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) - Business Wire
- 23 days ago - Adicet Bio, Inc. - Special Call - Seeking Alpha
- 23 days ago - Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 - Benzinga
- 23 days ago - Adicet Bio, Inc. Announces $80 Million Registered Direct Offering - Business Wire
- 23 days ago - Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - Business Wire
- 4 weeks ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire